Angiex is pioneering a new approach to cancer therapy: vascular targeting. Angiex is making an antibody-drug conjugate (ADC) therapy against a novel target expressed by tumor endothelial cells and by most tumor cells.

In preclinical studies, Angiex ADCs have shown an ability to regress human xenograft and mouse syngeneic tumors. If toxicity to the normal vasculature can be limited, Angiex's ADC has the potential to provide an effective treatment for all solid tumors.

2016 Boston Sidecar Winner
Sub industry